Overview

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Status:
Not yet recruiting

Trial end date:
2030-03-21

Target enrollment:

Participant gender:

Summary

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS of participants receiving standard of care (SOC) chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Blinatumomab